medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2022, Number 1

<< Back Next >>

Rev Med UAS 2022; 12 (1)

Prevalence of high risk human papilloma virus in healthy patients with vulvar condylomatosis

Acosta-Escalante JB, Monarrez-Manrriquez D, Morgan-Ortiz F, Guicho-Samaniego MG, Quevedo-Castro E, López-Manjarrez G

Language: Spanish
References: 24
Page: 5-11
PDF size: 81.06 Kb.


ABSTRACT

Introduction: The present study describes the prevalence of high risk human papiloma virus in healty patients wiht vulvar condylomatosis. Objective: 1- Estimate the prevalence of high-risk viruses in patients with genital warts. Methodology Observational, descriptive, prolective study: descriptive survey. Fifty-six samples were analyzed in healthy patients with clinical presence of anogenital warts frome in a period from December 2017 to September 2019 in Culiacán, Sinaloa, Mexico. The test allows the detection of 13 genotypes of HPV 16, 18, 31, 33, 35, 39, 51, 52 56, 58, 59, 66 y 68. This test reports separately the other two high risk genotypes 16 and 18. Results: A total of 56 patients who presented clinical lesions compatible with human papillomavirus infection or such as genital warts or condylomata acuminata were analyzed. The average age of the patients was 26.5 (95% CI: 23.3 - 28.6) with an average body mass index of 27.5 Kg / m2 (95% CI: 26.4 - 28.6); the mean age of menarche was 12.6 years (95% CI: 12.1 - 13.0), with a start of sexual life at 17.2 years, (95% CI: 16.5 - 17.9), number of sexual partners of 2.3 (95% CI: 1.7 - 2.8) and the average number of pregnancies was 1.6 (95% CI: 0.3, 0.9) Conclusions: Analysis of the results suggests that there is no association between the presence of genital condylomatosis and high-risk human papillomaviruses. In contrast to other studies carried out, the viral genotypes with the highest prevalence correspond to the probe P3 HPV 31- 33- 35- 52- 58- which detected 57%. Second, the P1 probe for HPV 16 with a percentage of 42.3%


REFERENCES

  1. Doorbar J. Molecular biology of human papillomavirusinfection and cervical cancer. ClinSci (Lond) 2006; 110:525.

  2. Schiffman M, Castle PE, Jeronimo J, et al.Human papillomavirus and cervical cancer.Lancet 2007; 370:890.

  3. Franco EL, Duarte-Franco E, Ferenczy A.Cervical cancer: epidemiology, preventionand the role of human papillomavirus infection.CMAJ 2001; 164:1017.

  4. Beutner KR. Nongenital human papillomavirusinfections. Clin Lab Med 2000; 20:423.

  5. Sonnex C. Human papillomavirus infectionwith particular reference to genital disease. JClin Pathol 1998; 51:643.

  6. Muñoz N, Bosch FX, de Sanjosé S, et al.Epidemiologic classification of human papillomavirustypes associated with cervicalcancer. N Engl J Med 2003; 348:518.

  7. Orman D, de Martel C, Lacey CJ, et al. Globalburden of human papillomavirus and relateddiseases. Vaccine 2012; 30.

  8. Sanjosé S, Alemany L, Ordi J, et al.Worldwide human papillomavirus genotypeattribution in over 2000 cases of intraepithelialand invasive lesions of the vulva. Eur JCancer 2013; 49:3450.

  9. Koutsky L. Epidemiology of genital humanpapillomavirus infection. Am J Med 1997;

  10. 102:3.10. Gillison ML, Broutian T, Pickard RK, et al.Prevalence of oral HPV infection in theUnited States, 2009-2010. JAMA 2012;307:693.

  11. Sturgiss EA, Jin F, Martin SJ, et al. Prevalenceof other sexually transmissible infectionsin patients with newly diagnosed anogenitalwarts in a sexual health clinic. SexHealth 2010; 7:55.

  12. Winer RL, Kiviat NB, Hughes JP, et al. Developmentand duration of human papillomaviruslesions, after initial infection. J InfectDis 2005; 191:731.

  13. Weiss DA, Yang G, Myers JB, Breyer BN.Condyloma overgrowth caused by immunereconstitution inflammatory syndrome. Urology2009; 74:1013.

  14. Woodhall S, Ramsey T, Cai C, et al. Estimationof the impact of genital warts on healthrelatedquality of life. Sex Transm Infect2008; 84:161.

  15. Solomon D, Davey D, Kurman R, et al. The2001 Bethesda System: terminology for reportingresults of cervical cytology. JAMA2002; 287:2114.

  16. Saslow D, Runowicz CD, Solomon D, et al.American Cancer Society guideline for theearly detection of cervical neoplasia andcancer. CA Cancer J Clin 2002; 52:342.

  17. Martin-Hirsch P, Jarvis G, Kitchener H, LilfordR. Collection devices for obtaining cervicalcytology samples. Cochrane DatabaseSyst Rev 2000;

  18. Auborn KJ, Carter TH. Treatment of humanpapillomavirus gynecologic infections. ClinLab Med 2000; 20:407.

  19. Harper DM, Longacre MR, Noll WW, et al.Factors affecting the detection rate of humanpapillomavirus. Ann Fam Med 2003; 1:221.

  20. Nayar R, Wilbur DC. The Pap test and Bethesda2014. Cancer Cytopathol 2015;123:271.

  21. Heideman D, Snijders P, Berkhof J. Vaccinationagainst HPV: indications for womenand the impact on the cervical screening programme.BJOG 2008;

  22. Freedman M, Kroger A, Hunter P, et al. RecommendedAdult Immunization Schedule,United States, 2020. Ann Intern Med 2020;172:337.

  23. Saslow D, Andrews KS, Manassaram-BaptisteD, et al. Human papillomavirus vaccinationguideline update: American Cancer Societyguideline endorsement. CA Cancer JClin 2016; 66:375.

  24. Lei J, Ploner A, Elfström KM, et al. HPV Vaccinationand the Risk of Invasive CervicalCancer. N Engl J Med 2020; 383:1340.




2020     |     www.medigraphic.com